High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

This study is testing a combination of high-dose furmonertinib (a targeted lung cancer drug), bevacizumab (which cuts off blood supply to tumors), and intrathecal pemetrexed (chemotherapy injected directly into the spinal fluid) for people with EGFR-mutated non-small cell lung cancer (NSCLC) that has spread to the lining of the brain (meningeal metastasis). **You may be eligible if...** - You have confirmed NSCLC with a specific EGFR mutation (exon 19 deletion, L858R, or T790M) - You have been diagnosed with meningeal metastasis, confirmed by MRI or spinal fluid analysis - You have symptoms of elevated pressure in the brain (headache, dizziness, vomiting) - This is your first diagnosis of meningeal involvement **You may NOT be eligible if...** - You do not have an EGFR mutation - You have had prior treatment that has already targeted meningeal disease - Your overall health is too poor to tolerate intrathecal chemotherapy - You have contraindications to any of the three study drugs Talk to your doctor to see if this trial is right for you.